Abstract
Cannabinoids have been reported to alter the activities of immune cells in vitro and in vivo. These compounds may serve as ideal agents for adjunct treatment of pathological processes that have a neuroinflammatory component. As highly lipophilic molecules, they readily access the brain. Furthermore, they have relatively low toxicity and can be engineered to selectively target cannabinoid receptors. To date, two cannabinoid receptors have been identified, characterized and designated CB1 and CB2. CB1 appears to be constitutively expressed within the CNS while CB2 apparently is induced during inflammation. The inducible nature of expression of CB2 extends to microglia, the resident macrophages of the brain that play a critical role during early stages of inflammation in that compartment. Thus, the cannabinoid-cannabinoid receptor system may prove therapeutically manageable in ablating neuropathogenic disorders such as Alzheimers disease, multiple sclerosis, amyotrophic lateral sclerosis, HIV encephalitis, closed head injury, and granulomatous amebic encephalitis.
Keywords: Alzheimer's, amyotrophic lateral sclerosis, cannabinoids, cannabinoid receptors, granulomatous amebic encephalitis, HIV encephalitis, multiple sclerosis, neuroinflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Volume: 8 Issue: 3
Author(s): G. A. Cabral and L. Griffin-Thomas
Affiliation:
Keywords: Alzheimer's, amyotrophic lateral sclerosis, cannabinoids, cannabinoid receptors, granulomatous amebic encephalitis, HIV encephalitis, multiple sclerosis, neuroinflammation
Abstract: Cannabinoids have been reported to alter the activities of immune cells in vitro and in vivo. These compounds may serve as ideal agents for adjunct treatment of pathological processes that have a neuroinflammatory component. As highly lipophilic molecules, they readily access the brain. Furthermore, they have relatively low toxicity and can be engineered to selectively target cannabinoid receptors. To date, two cannabinoid receptors have been identified, characterized and designated CB1 and CB2. CB1 appears to be constitutively expressed within the CNS while CB2 apparently is induced during inflammation. The inducible nature of expression of CB2 extends to microglia, the resident macrophages of the brain that play a critical role during early stages of inflammation in that compartment. Thus, the cannabinoid-cannabinoid receptor system may prove therapeutically manageable in ablating neuropathogenic disorders such as Alzheimers disease, multiple sclerosis, amyotrophic lateral sclerosis, HIV encephalitis, closed head injury, and granulomatous amebic encephalitis.
Export Options
About this article
Cite this article as:
Cabral A. G. and Griffin-Thomas L., Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/187153008785700118
DOI https://dx.doi.org/10.2174/187153008785700118 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypocholesterolemia
Current Vascular Pharmacology Inflammation and Innate Immune Response Against Viral Infections in Marine Fish
Current Pharmaceutical Design Beneficial Neurobiological Effects of Melatonin Under Conditions of Increased Oxidative Stress
Current Medicinal Chemistry - Central Nervous System Agents Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects
Current Pharmaceutical Design STAT3 and Its Phosphorylation are Involved in HIV-1 Tat-Induced Transactivation of Glial Fibrillary Acidic Protein
Current HIV Research Epigenetic Drugs for Multiple Sclerosis
Current Neuropharmacology Expression of Signaling Molecules in Progressive Multifocal Leukoencephalopathy
Current HIV Research Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
CNS & Neurological Disorders - Drug Targets Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism β-Catenin/TCF-4 Signaling Regulates Susceptibility of Macrophages and Resistance of Monocytes to HIV-1 Productive Infection
Current HIV Research Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews Current Status of Anti-Picornavirus Therapies
Current Pharmaceutical Design Stem Cells as a Potential Therapeutic Option for Treating Neurodegenerative Diseases
Current Stem Cell Research & Therapy Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research
Current Medicinal Chemistry Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science The Microbiota and Gut-Brain Axis: Contributions to the Immunopathogenesis of Schizophrenia
Current Pharmaceutical Design Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets Functions of Antimicrobial Peptides in Vertebrates
Current Protein & Peptide Science